

angles  $2\theta$  of 8.5, 13.4, 19.1 and 24.5°;

(b) an infrared absorption spectrum showing characteristic absorption bands at 916, 1146, 1167, 1295, 1651, 1664, 2909, 2955, 3003 and 3146  $\text{cm}^{-1}$ ; and

(c) a melting point of 199 to 201°C,

the method comprising: dissolving 3-cyclopropyl-6-{(1R)-1-[4-(1,1-difluoroethyl)phenyl]-2-[(2R)-5-oxopyrrolidin-2-yl]ethyl}pyridin-2(1H)-one represented by the above formula [1] in an alcohol solvent while heating, to provide a solution; thereafter, adding a water solvent to the solution; cooling the resultant solution to 5°C or lower to yield a crystal; and drying the obtained crystal at 60°C or lower.

[Claim 5]

A medicine comprising, as an active ingredient, the 2-pyridone compound, a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate of the 2-pyridone compound or the relatives according to claim 1.

[Claim 6]

The medicine according to claim 5, wherein the medicine is a prophylactic or therapeutic agent for a disease or condition that can be improved by a glucokinase activating effect.

[Claim 7]

The medicine according to claim 5, which is a hypoglycemic agent.

[Claim 8]

The medicine according to claim 5, wherein the medicine is a prophylactic or therapeutic agent for diabetes.

[Claim 9]

Use of the 2-pyridone compound, a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate of the 2-pyridone compound or the relatives according to claim 1 in the manufacture of a medicament for preventing or treating a disease or condition that can be improved by a glucokinase activating effect diabetes-related diseases such as obesity and hyperlipidemia or chronic diabetic complications such as retinopathy, nephropathy and arteriosclerosis.

[Claim 10]

Use of the 2-pyridone compound, a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate of the 2-pyridone compound or the relatives according to claim 1 in the manufacture of a medicament for preventing or treating diabetes.